Trulieve Cannabis (TCNNF) Total Non-Current Liabilities (2020 - 2026)
Trulieve Cannabis (TCNNF) recorded quarterly Total Non-Current Liabilities of $936.2 million in Q1 2026, down 39.27% quarter-over-quarter from $1.5 billion in Q4 2025, and down 2.58% on a YoY basis from $961.0 million in Q1 2025.
Trulieve Cannabis (TCNNF) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Trulieve Cannabis' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $936.2 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 2.58% year-over-year to $936.2 million; the TTM figure through Mar 2026 stood at $936.2 million (down 2.58% YoY), while the FY2025 annual figure was $1.5 billion, down 4.62% from the prior year.
- Total Non-Current Liabilities was $936.2 million for Q1 2026 at Trulieve Cannabis, down from $1.5 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.7 billion in Q3 2025 to a low of $777.7 million in Q4 2023.
- Historically, Total Non-Current Liabilities has averaged $1.3 billion across 5 years, with a median of $1.3 billion in 2022.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities jumped 277.5% in 2022, then slumped 45.65% in 2023.
- A 5-year view of Total Non-Current Liabilities shows it stood at $1.4 billion in 2022, then slumped by 45.65% to $777.7 million in 2023, then surged by 107.83% to $1.6 billion in 2024, then declined by 4.62% to $1.5 billion in 2025, then sank by 39.27% to $936.2 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $936.2 million (Q1 2026), $1.5 billion (Q4 2025), and $1.7 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Trulieve Cannabis | - | - | 170.08 Mn | 936.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 936.23 Mn |
| Dec 31, 2025 | 1.54 Bn |
| Sep 30, 2025 | 1.74 Bn |
| Jun 30, 2025 | 969.72 Mn |
| Mar 31, 2025 | 961.05 Mn |
| Dec 31, 2024 | 1.62 Bn |
| Sep 30, 2024 | 1.56 Bn |
| Jun 30, 2024 | 1.16 Bn |
| Mar 31, 2024 | 848.48 Mn |
| Dec 31, 2023 | 777.68 Mn |
| Sep 30, 2023 | 1.25 Bn |
| Jun 30, 2023 | 1.35 Bn |
| Mar 31, 2023 | 1.41 Bn |
| Dec 31, 2022 | 1.43 Bn |
| Sep 30, 2022 | 1.30 Bn |
| Jun 30, 2022 | 1.34 Bn |
| Mar 31, 2022 | 1.40 Bn |
| Dec 31, 2021 | 1.26 Bn |
| Sep 30, 2021 | 446.96 Mn |
| Jun 30, 2021 | 360.10 Mn |